Unlocking the future of hepatocellular carcinoma treatment: A comprehensive analysis of disulfidptosis-related lncRNAs for prognosis and drug screening.
Wang H, Wang W.
Open Med (Wars) · research-article; journal article · DOI 10.1515/med-2024-0919 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för YK-4-279. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
20 hitsPan-cancer analysis of Sushi domain-containing protein 4 (SUSD4) and validated in colorectal cancer.
Zhong Y, Zheng C, Zhang W, Wu H, Zhang Q, Li D, Ju H, Feng H, Chen Y, Fan Y, Chen W, Wang M, Wang G.
Aging (Albany NY) · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/aging.205712Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.
Minas TZ, Han J, Javaheri T, Hong SH, Schlederer M, Saygideğer-Kont Y, Çelik H, Mueller KM, Temel I, Özdemirli M, Kovar H, Erkizan HV, Toretsky J, Kenner L, Moriggl R, Üren A.
Oncotarget · published erratum; correction; journal article · DOI 10.18632/oncotarget.28524YK-4-279 Attenuates Progression of Pre-Existing Pigmented Lesions to Nodular Melanoma in a Mouse Model.
Huang L, Zhai Y, Fajardo CD, Lang D.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers14010143The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of <i>TERT</i> Promoter Mutations.
Xue J, Li S, Shi P, Chen M, Yu S, Hong S, Li Y, Liu R, Xiao H.
Front Oncol · research-article; journal article · DOI 10.3389/fonc.2021.649323Targeting Pan-ETS Factors Inhibits Melanoma Progression.
Huang L, Zhai Y, La J, Lui JW, Moore SPG, Little EC, Xiao S, Haresi AJ, Brem C, Bhawan J, Lang D.
Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-19-1668An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression.
Schafer CM, Gurley JM, Kurylowicz K, Lin PK, Chen W, Elliott MH, Davis GE, Bhatti F, Griffin CT.
Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.2015980117Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
Conn E, Hour S, Allegakoen D, Graham G, Petro J, Kouassi-Brou M, Hong SH, Selvanathan S, Çelik H, Toretsky J, Üren A.
Mol Med Rep · research-article; journal article · DOI 10.3892/mmr.2020.10948The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, Stathis A, Lannutti B, Toretsky JA, Bertoni F.
Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-18-2718EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma.
Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, Rajapakshe K, Xu X, Huang W, Agarwal S, Patel RH, Woodfield S, Zhao Y, Jin J, Zhang H, Major A, Hicks MJ, Shohet JM, Vasudevan SA, Coarfa C, Yang J, Nuchtern JG.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.21933Inhibition of the oncogenic fusion protein EWS-FLI1 causes G<sub>2</sub>-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.
Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.
Sci Signal · research-article; journal article · DOI 10.1126/scisignal.aam8429Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
Winters B, Brown L, Coleman I, Nguyen H, Minas TZ, Kollath L, Vasioukhin V, Nelson P, Corey E, Üren A, Morrissey C.
Anticancer Res · journal article · DOI 10.21873/anticanres.11705The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.
Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J, Kaidi A, Malik K.
Cancer Lett · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.canlet.2017.05.027The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
Yu L, Wu X, Chen M, Huang H, He Y, Wang H, Li D, Du Z, Zhang K, Goodin S, Zheng X.
Int J Med Sci · research-article; journal article · DOI 10.7150/ijms.18382YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.
Minas TZ, Han J, Javaheri T, Hong SH, Schlederer M, Saygideğer-Kont Y, Çelik H, Mueller KM, Temel I, Özdemirli M, Kovar H, Erkizan HV, Toretsky J, Kenner L, Moriggl R, Üren A.
Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.5520An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.
Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Aiyer RA, Maywald RL, Buford AS, Doolittle DK, Culotta KS, O'Dorisio JE, Ludwig JA.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-14-0334A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S, Minas T, Hong SH, Justvig S, Çelik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, Brown ML, Kallakury B, Toretsky JA, Üren A.
PLoS One · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0114260Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.
Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, Kobs CL, South NL, Summer S, Monroe PJ, Chruszcz M, Dobrev V, Tosso PN, Scher LJ, Minor W, Brown ML, Metallo SJ, Üren A, Toretsky JA.
Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.454YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A.
PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0019343A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.
Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA.
Nat Med · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nm.1983